ClinicalTrials.gg
CompletedNCT02831764Updated Dec 7, 2023Results posted

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

A Phase 3 interventional study of Dolutegravir (DTG) and Lamivudine (3TC) in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 105 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-07.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
722
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
14th of 126
722 · median 154
Started
2016
with 1 other
Phase 3
50 of 132
2 open now
Registered
111th of 132
by date
Lead sponsor
13 of 132
ViiV Healthcare

Among the 132 studies testing lamivudine in HIV Infections, this one is the 14th largest by enrollment of the 126 interventional ones that give a count, is one of 2 that started in 2016, is one of 50 in phase 3, and was the 111th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (tenofovir disoproxil fumarate [TDF]/emtricitabine [FTC] fixed dose combination [FDC]) administered once daily in human immunodeficiency virus (HIV) 1 infected adult participants that have not previously received antiretroviral therapy. The study is designed to demonstrate the non inferior antiviral activity of DTG + 3TC regimen to that of DTG + TDF/FTC FDC and will characterise the long term antiviral activity, tolerability and safety of DTG plus 3TC through Week 148. Approximately, 700 participants will be randomised 1:1 to receive DTG + 3TC or DTG + TDF/FTC FDC. Participants will be stratified by screening HIV 1 ribonucleotide nucleic acid (RNA) levels and by screening CD4+ (cluster of differentiation 4) cell count.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Browse trials for

Keywords

  • tolerability
  • HIV 1
  • efficacy
  • treatment naïve
  • two-drug regimen
  • safety
  • non inferiority
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's enrollment of 722 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be an 1 infected adult >=18 years of age (or older, if required by local regulations) at the time of signing the
  • An eligible female participant should not be pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test at Screening and negative urine test at Baseline), not lactating, and at least one of the following conditions applies

    • Non reproductive premenopausal women are those that have undergone documented tubal ligation or documented hysteroscopic tubal occlusion procedure with follow up confirmation of bilateral tubal occlusion or documented bilateral oophorectomy or hysterectomy
    • Non reproductive premenopausal women are those with 12 months of spontaneous amenorrhea and >=45 years of age
    • Women with agree to follow one of the protocol-defined methods for avoiding pregnancy
  • Should have screening plasma HIV 1 RNA levels of 1000 c/mL to \<=100,000 c/mL. If an independent review of accumulated data from other clinical trials investigating the DTG plus 3TC dual regimen is supportive of the DTG plus 3TC treatment regimen, enrolment will be opened to participants with Screening plasma HIV 1 RNA of 1000 c/mL to \<=500,000 c/mL
  • Participant should be antiretroviral naïve (defined as \<=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV 1 infection). Participants who received HIV post exposure prophylaxis (PEP) or pre exposure prophylaxis (PrEP) in the past are allowed as long as the last PEP/PrEP dose was >1 year from HIV diagnosis or there is documented HIV seronegativity between the last prophylactic dose and the date of HIV diagnosis
  • Participants or the participants legal representative capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and the protocol
  • Participants enrolled in France: a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category

Exclusion criteria

Exclusion Criteria

  • Women who are breastfeeding or plan to become pregnant or breastfeed during the study
  • Any evidence of an active centers for disease control and prevention (CDC) Stage 3 disease (CDC, 2014), except cutaneous Kaposi's sarcoma not requiring systemic therapy and historical or current less than 200 cells/mm\^3
  • Participants with severe hepatic impairment (Class C) as determined by classification
  • Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones
  • Evidence of virus (HBV) infection or HBV surface antibody (anti-HBs or HBsAb) based on:

Participants positive for HBV surface antigen (HBsAg) at screening will be excluded Participants negative for HBV core antibody (anti HBs) but positive for anti HBc (negative HBsAg status) and positive for HBV deoxyribose nucleic acid (DNA) will be excluded; however, participants positive for anti HBc (negative HBsAg status) and positive for anti HBs (past and/or current evidence) are immune to HBV and will not be excluded

  • Anticipated need for any virus (HCV) therapy during the first 48 weeks of the study and for HCV therapy based on interferon or any drugs that have a potential for adverse drug:drug interactions with study treatment throughout the entire study period
  • Untreated syphilis infection positive RPR at Screening without clear documentation of treatment. Participants who are at least 14 days post completed treatment are eligible
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; other localised malignancies require agreement between the investigator and the Study Medical Monitor for inclusion of the participant
  • Participants who in the Investigator's judgment, poses a significant suicidality risk. Recent history of suicidal behaviour and/or suicidal ideation may be considered as evidence of serious suicide risk
  • Treatment with an 1 immunotherapeutic vaccine within 90 days of Screening
  • Treatment with any of the following agents within 28 days of Screening:

    • Radiation therapy,
    • Cytotoxic chemotherapeutic agents,
    • Any systemic immune suppressant
  • Treatment with any agent, except recognised ART as allowed above, with documented activity against HIV 1 in vitro within 28 days of first dose of study treatment
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study treatment
  • Participants enrolled in France: the participant has participated in any study using an drug during the previous 60 days or 5 half lives, or twice the duration of the biological effect of the experimental drug or vaccine, whichever is longer, prior to screening for the study or the participant will participate simultaneously in another clinical study
  • Any evidence of pre existing viral resistance based on the presence of any major resistance associated mutation in the Screening result or, if known, in any historical resistance test result
  • Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening period to verify a result
  • Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the participants participation in the study of an investigational compound
  • (ALT) >=5 times the (ULN) or ALT >=3xULN and >=1.5xULN (with >35% direct bilirubin)
  • of \<50 mL/min per 1.73 m\^2 via the chronic kidney disease epidemiology collaboration (CKD EPI) method
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
722 participants (actual)

Study arms

  • Experimental
    DTG + 3TC (50 mg+300 mg

    Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the participant no longer derives clinical benefit, or (iv) the participant meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.

    Drug: Dolutegravir (DTG) · Drug: Lamivudine (3TC)

  • Active comparator
    DTG + TDF/FTC FDC (50 mg+300/200 mg)

    Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).

    Drug: Dolutegravir (DTG) · Drug: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

Interventions

  • DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.

  • Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.

  • DrugTenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

    Drug pages: Tenofovir · Emtricitabine

    Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel (CMH) weights. Intent-To-Treat Exposed (ITT-E) Population was used which comprised of all randomized participants who received at least one dose of study treatment. Percentage values are rounded off.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

    Time frame: Week 24

  2. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

    Time frame: Week 96

  3. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

    Time frame: Week 144

  4. Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144

    Time of viral suppression is defined as the first viral load value \<50 c/mL. Nonparametric Kaplan-Meier method was performed. Participants who withdrew for any reason without being suppressed were censored at date of withdrawal. Participants who have not been withdrawn and have not had viral suppression at time of the analysis were censored at last viral load date. Confidence Interval (CI) was estimated using the Brookmeyer-Crowley method.

    Time frame: Up to Week 144

  5. CD4+ Cell Counts at Weeks 24 and 48

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

    Time frame: Weeks 24 and 48

  6. CD4+ Cell Counts at Week 96

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

    Time frame: Week 96

  7. CD4+ Cell Counts at Week 144

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

    Time frame: Week 144

  8. Changes From Baseline in CD4+ Cell Counts at Week 24 and 48

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted least mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

    Time frame: Baseline and Weeks 24, 48

  9. Changes From Baseline in CD4+ Cell Counts at Week 96

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

    Time frame: Baseline and Week 96

  10. Changes From Baseline in CD4+ Cell Counts at Week 144

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

    Time frame: Baseline and Week 144

  11. Number of Participants With HIV-1 Disease Progression up to Week 144

    HIV-associated conditions were recorded during the study and was assessed according to the 2014 Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. Disease progressions summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrolment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrolment to Death. Participants may have more than one indicators of clinical disease progression including death, hence they may contribute to data in more than one categories.

    Time frame: Up to Week 144

  12. Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144

    Number of participants, who met confirmed virologic withdrawal (CVW) criteria, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI) and/or Nucleoside reverse transcriptase inhibitor (NRTI) was summarized. The Viral Genotypic Population comprised of all participants in the ITT-E population who have available on-treatment genotypic resistance data.

    Time frame: Up to Week 144

  13. Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144

    Number of participants, who met CVW criteria, with treatment emergent phenotypic resistance to INSTI and/or NRTI were summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results were interpreted through a proprietary algorithm (from Monogram Biosciences) and provides the overall susceptibility of the drugs (DTG, 3TC, Abacavir \[ABC\], elvitegravir \[EGV\], raltegravir \[RAL\], zidovudine \[AZT\], stavudine \[D4T\], didanosine \[DDI\]), emtricitabine \[FTC\], tenofovir disiproxil fumarate \[TDF\]). Partially sensitive and resistant cells were considered resistant in this analysis. The Viral Phenotypic Population comprised of all participants in the ITT-E population who have available on-treatment phenotypic resistance data.

    Time frame: Up to Week 144

  14. Number of Participants With Any Adverse Event (AE) and Serious AE (SAE) up to Week 148

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or protocol-defined event associated with liver injury and impaired liver function were categorized as SAE. Safety Population was used which comprised of all participants who received at least one dose of study treatment.

    Time frame: Up to Week 148

  15. Number of Participants With AEs by Maximum Severity Grades up to Week 148

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

    Time frame: Up to Week 148

  16. Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 148

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5. (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with drug related AEs and drug related AEs by by maximum grade have been presented.

    Time frame: Up to Week 148

  17. Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144

    Blood samples were collected up to Week 144 for assessment of hemoglobin, leukocytes, neutrophils and platelet count. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the listed hematology parameters have been presented.

    Time frame: Up to Week 144

  18. Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144

    Blood samples were collected up to Week 144 for assessment of Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin, Carbon dioxide (CO2), Cholesterol, Creatine kinase (CK), Creatinine, Direct Bilirubin, Glomerular filtration rate (GFR), Hypercalcemia, Hyperglycemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycemia, Hypokalemia, Hyponatremia, Low density lipid (LDL) Cholesterol, Lactate Dehydrogenase, Lipase, Phosphate, and Triglycerides. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent chemistry toxicities in any of the chemistry parameters have been presented.

    Time frame: Up to Week 144

  19. Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.

    Time frame: Up to Weeks 24, 48 and 96

  20. Number of Participants Who Discontinue Treatment Due to AEs Over Week 144

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.

    Time frame: Up to Week 144

  21. Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48

    Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C and Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and at Weeks 24, 48

  22. Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96

    Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.

    Time frame: Baseline and at Week 96

  23. Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144

    Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.

    Time frame: Baseline and at Week 144

  24. Change From Baseline in Renal Biomarker-Serum RBP at Week 96

    Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and at Week 96

  25. Change From Baseline in Renal Biomarker-Serum RBP at Week 144

    Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and at Week 144

  26. Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48

    Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI (GFR-cystatin C adjusted) and Serum or Plasma GFR from creatinine adjusted using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and at Weeks 24, 48

  27. Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96

    Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and at Week 96

  28. Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144

    Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and at Week 144

  29. Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48

    Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and at Weeks 24, 48

  30. Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96

    Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented.

    Time frame: Baseline and at Week 96

  31. Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144

    Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented.

    Time frame: Baseline and at Week 144

  32. Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Geometric mean ratio and 95% CI of geometric mean ratio have been presented. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and Weeks 24, 48

  33. Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and Week 96

  34. Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline and at Week 144

  35. Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48

    Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  36. Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96

    Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 96

  37. Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144

    Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 144

  38. Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48

    Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.

    Time frame: Baseline and at Weeks 24, 48

  39. Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96

    Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.

    Time frame: Baseline and at Week 96

  40. Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144

    Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.

    Time frame: Baseline and at Week 144

  41. Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma High Density Lipoprotein (HDL) Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48

    Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value is defined as the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value).

    Time frame: Baseline and at Weeks 24, 48

  42. Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96

    Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 96

  43. Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144

    Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 144

  44. Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48

    Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value). Lipid last observation carried forwarded (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Participants on lipid-lowering agents at Baseline were excluded.

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  45. Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96

    Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 96

  46. Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144

    Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 144

  47. Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48

    Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24 and 48 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 48 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.

    Time frame: Weeks 24 and 48

  48. Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96

    Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 96 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 96 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.

    Time frame: Week 96

  49. Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144

    Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 144 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 144 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.

    Time frame: Week 144

  50. Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24

    Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3 for group-1), Baseline HIV-1 RNA (\<=100000, \>100000 c/mL) and Race (White, African American/African heritage (H.), Asian other). Percentage values are rounded-off.

    Time frame: Week 24

  51. Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48

    Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3 for group-1), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.

    Time frame: Week 48

  52. Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96

    Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.

    Time frame: Week 96

  53. Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144

    Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.

    Time frame: Week 144

  54. Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

    Time frame: Baseline (Day 1) and Week 24

  55. Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from Analysis of Covariance (ANCOVA) model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

    Time frame: Baseline (Day 1) and Week 48

  56. Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

    Time frame: Baseline (Day 1) and Week 96

  57. Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

    Time frame: Baseline (Day 1) and Week 144

  58. Change From Baseline in European Quality of Life [EuroQoL] - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48

    EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value.

    Time frame: Baseline (Day 1) and Weeks 4, 24, 48

  59. Change From Baseline in EQ-5D-5L Utility Score at Week 96

    EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and Week 96

  60. Change From Baseline in EQ-5D-5L Utility Score at Week 144

    EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and Week 144

  61. Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24, 48

    EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value.

    Time frame: Baseline (Day 1) and Weeks 4, 24, 48

  62. Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96

    EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and Week 96

  63. Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144

    EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and Week 144

08

Results

Posted Apr 22, 2019

Participant flow

This study is a Phase 3, randomized, double-blind, parallel group, non-inferiority study. The study consisted of double-blind phase, open-label phase and continuation phase.

Double-blind Phase (Day1 to Week 96)
Participant flow — Double-blind Phase (Day1 to Week 96)
MilestoneDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind PhaseDTG + 3TC - Open-label PhaseDTG + TDF/FTC - Open-label PhaseDTG + 3TC - Continuation Phase
Started360362000
Intent-to-treat exposed360359000
Completed319327000
Not completed4135000
Withdrew: Protocol specific withdrawal criteria02000
Withdrew: Withdrawal by subject99000
Withdrew: Physician decision33000
Withdrew: Lost to follow-up97000
Withdrew: Adverse event106000
Withdrew: Lack of efficacy52000
Withdrew: Protocol deviation53000
Withdrew: Randomized, but did not receive treatment03000
Open-label Phase (Week 96 to Week 148)
Participant flow — Open-label Phase (Week 96 to Week 148)
MilestoneDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind PhaseDTG + 3TC - Open-label PhaseDTG + TDF/FTC - Open-label PhaseDTG + 3TC - Continuation Phase
Started003193270
Completed003013000
Not completed0018270
Withdrew: Adverse event00160
Withdrew: Lack of efficacy00200
Withdrew: Protocol deviation00220
Withdrew: Protocol-specified withdrawal criteria00100
Withdrew: Lost to follow-up00470
Withdrew: Physician decision00130
Withdrew: Withdrawal by subject00790
Continuation Phase(Week 148 to Week 280)
Participant flow — Continuation Phase(Week 148 to Week 280)
MilestoneDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind PhaseDTG + 3TC - Open-label PhaseDTG + TDF/FTC - Open-label PhaseDTG + 3TC - Continuation Phase
Started0000252
Completed0000239
Not completed000013
Withdrew: Protocol deviation00001
Withdrew: Lost to follow-up00002
Withdrew: Physician decision00005
Withdrew: Withdrawal by subject00005

Outcome measures

PrimaryPercentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel (CMH) weights. Intent-To-Treat Exposed (ITT-E) Population was used which comprised of all randomized participants who received at least one dose of study treatment. Percentage values are rounded off.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48
Percentage of participantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 4893 (90.4 to 95.7)94 (91.4 to 96.4)
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Adjusted difference in proportion: -0.7 · 95% CI -4.3 to 2.9Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (\<= vs. \>100,000 copies per milliliter) and CD4+ cell count (\<= vs. \>200 cells per cubic millimeter \[cells/mm\^3\]).
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 2494 (91.4 to 96.4)94 (91.4 to 96.4)
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Adjusted difference in proportion: 0.1 · 95% CI -3.4 to 3.6Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (\<= vs. \>100,000 c/mL) and CD4+ cell count (\<= vs. \>200 cells/mm\^3).
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
Percentage of participantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 9688 (84.4 to 91.2)90 (86.5 to 92.8)
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Adjusted difference in proportion: -1.8 · 95% CI -6.4 to 2.7Week 96. Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (\<= vs. \>100,000 c/mL) and CD4+ cell count (\<= vs. \>200 cells/mm\^3).
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
Percentage of participantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 14484 (80.4 to 87.9)84 (80.6 to 88.2)
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Adjusted difference in proportion: 0.0 · 95% CI -5.3 to 5.3Week 144. Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (\<= vs. \>100,000 c/mL) and CD4+ cell count (\<= vs. \>200 cells/mm\^3).
SecondaryTime to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144

Time of viral suppression is defined as the first viral load value \<50 c/mL. Nonparametric Kaplan-Meier method was performed. Participants who withdrew for any reason without being suppressed were censored at date of withdrawal. Participants who have not been withdrawn and have not had viral suppression at time of the analysis were censored at last viral load date. Confidence Interval (CI) was estimated using the Brookmeyer-Crowley method.

Time frame:
Up to Week 144
Reported as:
Median · Days
Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144
DaysDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 14429.0 (29.0 to 55.0)29.0 (29.0 to 57.0)
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Generalised Wilcoxon procedure · p = 0.797 (The generalised Wilcoxon procedure was used to estimate a p-value for detecting a difference in cumulative incidence curves between treatment groups.) · Hazard ratio (hr): 1.02 · 95% CI 0.88 to 1.19Hazard ratios were estimated using the Cox proportional hazard regression model.
SecondaryCD4+ Cell Counts at Weeks 24 and 48

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

Time frame:
Weeks 24 and 48
Reported as:
Mean · Cells/mm^3
CD4+ Cell Counts at Weeks 24 and 48
Cells/mm^3DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Week 24, n=349,345650.4 ± 257.02633.0 ± 287.37
Week 48, n=337,340688.1 ± 266.39689.8 ± 308.49
SecondaryCD4+ Cell Counts at Week 96

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

Time frame:
Week 96
Reported as:
Mean · Cells/mm^3
CD4+ Cell Counts at Week 96
Cells/mm^3DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
CD4+ Cell Counts at Week 96734.9 ± 270.82739.9 ± 299.80
SecondaryCD4+ Cell Counts at Week 144

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

Time frame:
Week 144
Reported as:
Mean · Cells/mm^3
CD4+ Cell Counts at Week 144
Cells/mm^3DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
CD4+ Cell Counts at Week 144763.8 ± 266.61770.4 ± 332.65
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 24 and 48

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted least mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

Time frame:
Baseline and Weeks 24, 48
Reported as:
Least squares mean · Cells/mm^3
Changes From Baseline in CD4+ Cell Counts at Week 24 and 48
Cells/mm^3DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Week 24, n=349, 345188.8 ± 8.77163.2 ± 9.08
Week 48, n=337, 340225.7 ± 8.94217.2 ± 9.93
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mixed Model Repeated Measures (MMRM) · p = 0.043 · Mean difference (net): 25.6 · 95% CI 0.8 to 50.4Week 24. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.523 · Mean difference (net): 8.5 · 95% CI -17.7 to 34.8Week 48. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 96

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

Time frame:
Baseline and Week 96
Reported as:
Mean · Cells/mm^3
Changes From Baseline in CD4+ Cell Counts at Week 96
Cells/mm^3DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Changes From Baseline in CD4+ Cell Counts at Week 96272.0 ± 10.83264.6 ± 11.18
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mixed Model Repeated Measures (MMRM) · p = 0.635 · Mean difference (net): 7.4 · 95% CI -23.2 to 38.0Week 96. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 144

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

Time frame:
Baseline and Week 144
Reported as:
Mean · Cells/mm^3
Changes From Baseline in CD4+ Cell Counts at Week 144
Cells/mm^3DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Changes From Baseline in CD4+ Cell Counts at Week 144301.7 ± 11.55296.6 ± 13.55
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.777 · Mean difference (net): 5.1 · 95% CI -29.9 to 40.0Week 144.Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.
SecondaryNumber of Participants With HIV-1 Disease Progression up to Week 144

HIV-associated conditions were recorded during the study and was assessed according to the 2014 Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. Disease progressions summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrolment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrolment to Death. Participants may have more than one indicators of clinical disease progression including death, hence they may contribute to data in more than one categories.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With HIV-1 Disease Progression up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
No disease progression356357
From CDC Stage 1 to CDC Stage 3 Event00
From CDC Stage 2 to CDC Stage 3 Event21
From CDC Stage 3 to New CDC Stage 3 Event10
From CDC Stage 1, 2 or 3 to Death21
SecondaryNumber of Participants With Treatment-emergent Genotypic Resistance up to Week 144

Number of participants, who met confirmed virologic withdrawal (CVW) criteria, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI) and/or Nucleoside reverse transcriptase inhibitor (NRTI) was summarized. The Viral Genotypic Population comprised of all participants in the ITT-E population who have available on-treatment genotypic resistance data.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
INSTI Mutations00
Major mutations of the NRTI00
SecondaryNumber of Participants With Treatment-emergent Phenotypic Resistance up to Week 144

Number of participants, who met CVW criteria, with treatment emergent phenotypic resistance to INSTI and/or NRTI were summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results were interpreted through a proprietary algorithm (from Monogram Biosciences) and provides the overall susceptibility of the drugs (DTG, 3TC, Abacavir \[ABC\], elvitegravir \[EGV\], raltegravir \[RAL\], zidovudine \[AZT\], stavudine \[D4T\], didanosine \[DDI\]), emtricitabine \[FTC\], tenofovir disiproxil fumarate \[TDF\]). Partially sensitive and resistant cells were considered resistant in this analysis. The Viral Phenotypic Population comprised of all participants in the ITT-E population who have available on-treatment phenotypic resistance data.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
INSTI, DTG, Sensitive, n=7,272
INSTI, DTG, Resistant, n=7,200
INSTI, EGV, Sensitive, n=7,272
INSTI, EGV, Resistant, n=7,200
INSTI, RAL, Sensitive, n=7,272
INSTI, RAL, Resistant, n=7,200
NRTI, 3TC, Sensitive, n=7,373
NRTI, 3TC, Resistant, n=7,300
NRTI, ABC, Sensitive, n=7,373
NRTI, ABC, Resistant, n=7,300
NRTI, AZT, Sensitive, n=7,373
NRTI, AZT, Resistant, n=7,300
NRTI, D4T, Sensitive, n=7,373
NRTI, D4T, Resistant, n=7,300
NRTI, DDI, Sensitive, n=7,373
NRTI, DDI, Resistant, n=7,300
NRTI, FTC, Sensitive, n=7,373
NRTI, FTC, Resistant, n=7,300
NRTI, TDF, Sensitive, n=7,373
NRTI, TDF, Resistant, n=7,300
SecondaryNumber of Participants With Any Adverse Event (AE) and Serious AE (SAE) up to Week 148

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or protocol-defined event associated with liver injury and impaired liver function were categorized as SAE. Safety Population was used which comprised of all participants who received at least one dose of study treatment.

Time frame:
Up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Event (AE) and Serious AE (SAE) up to Week 148
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Any AE306309
Any SAE3947
SecondaryNumber of Participants With AEs by Maximum Severity Grades up to Week 148

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

Time frame:
Up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With AEs by Maximum Severity Grades up to Week 148
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Grade 1 AEs5454
Grade 2 AEs211205
Grade 3 AEs3243
Grade 4 AEs76
Grade 5 AEs21
SecondaryNumber of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 148

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5. (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with drug related AEs and drug related AEs by by maximum grade have been presented.

Time frame:
Up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 148
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Any drug related AE6991
Drug related AEs with maximum toxicity Grade 13753
Drug related AEs with maximum toxicity Grade 22629
Drug related AEs with maximum toxicity Grade 358
Drug related AEs with maximum toxicity Grade 411
Drug related AEs with maximum toxicity Grade 500
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144

Blood samples were collected up to Week 144 for assessment of hemoglobin, leukocytes, neutrophils and platelet count. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the listed hematology parameters have been presented.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Hemoglobin, Grades 1 to 4810
Hemoglobin, Grades 2 to 466
Hemoglobin, Grades 3 to 421
Hemoglobin, Grade 124
Hemoglobin, Grade 245
Hemoglobin, Grade 311
Hemoglobin, Grade 410
Leukocytes, Grades 1 to 455
Leukocytes, Grades 2 to 410
Leukocytes, Grades 3 to 400
Leukocytes, Grade 145
Leukocytes, Grade 210
Leukocytes, Grade 300
Leukocytes, Grade 400
Neutrophils, Grades 1 to 4237
Neutrophils, Grades 2 to 483
Neutrophils, Grades 3 to 441
Neutrophils, Grade 1154
Neutrophils, Grade 242
Neutrophils, Grade 321
Neutrophils, Grade 420
Platelets, Grades 1 to 4139
Platelets, Grades 2 to 455
Platelets, Grades 3 to 400
Platelets, Grade 184
Platelets, Grade 255
Platelets, Grade 300
Platelets, Grade 400
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144

Blood samples were collected up to Week 144 for assessment of Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin, Carbon dioxide (CO2), Cholesterol, Creatine kinase (CK), Creatinine, Direct Bilirubin, Glomerular filtration rate (GFR), Hypercalcemia, Hyperglycemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycemia, Hypokalemia, Hyponatremia, Low density lipid (LDL) Cholesterol, Lactate Dehydrogenase, Lipase, Phosphate, and Triglycerides. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent chemistry toxicities in any of the chemistry parameters have been presented.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
ALT, Grades 1 to 47771
ALT, Grades 2 to 43029
ALT, Grades 3 to 41315
ALT, Grade 14742
ALT, Grade 21714
ALT, Grade 368
ALT, Grade 477
Albumin, Grades 1 to 421
Albumin, Grades 2 to 421
Albumin, Grades 3 to 401
Albumin, Grade 100
Albumin, Grade 220
Albumin, Grade 301
Albumin, Grade 400
ALP, Grades 1 to 41017
ALP, Grades 2 to 423
ALP, Grades 3 to 401
ALP, Grade 1814
ALP, Grade 222
ALP, Grade 301
ALP, Grade 400
AST, Grades 1 to 47183
AST, Grades 2 to 43032
AST, Grades 3 to 41514
AST, Grade 14151
AST, Grade 21518
AST, Grade 3811
AST, Grade 473
Bilirubin, Grades 1 to 44656
Bilirubin, Grades 2 to 41316
Bilirubin, Grades 3 to 443
Bilirubin, Grade 13340
Bilirubin, Grade 2913
Bilirubin, Grade 302
Bilirubin, Grade 441
CO2, Grades 1 to 4111111
CO2, Grades 2 to 4104
CO2, Grades 3 to 400
CO2, Grade 1101107
CO2, Grade 2104
CO2, Grade 300
CO2, Grade 400
Cholesterol, Grades 1 to 49850
Cholesterol, Grades 2 to 42312
Cholesterol, Grades 3 to 410
Cholesterol, Grade 17538
Cholesterol, Grade 22212
Cholesterol, Grade 310
Cholesterol, Grade 400
CK, Grades 1 to 49183
CK, Grades 2 to 44947
CK, Grades 3 to 42928
CK, Grade 14236
CK, Grade 22019
CK, Grade 31111
CK, Grade 41817
Creatinine, Grades 1 to 41828
Creatinine, Grades 2 to 452
Creatinine, Grades 3 to 401
Creatinine, Grade 11326
Creatinine, Grade 251
Creatinine, Grade 301
Creatinine, Grade 400
Direct Bilirubin, Grades 1 to 41110
Direct Bilirubin, Grades 2 to 41110
Direct Bilirubin, Grades 3 to 41110
Direct Bilirubin, Grade 100
Direct Bilirubin, Grade 200
Direct Bilirubin, Grade 31110
Direct Bilirubin, Grade 400
GFR, Grades 1 to 4198219
GFR, Grades 2 to 4198219
GFR, Grades 3 to 42029
GFR, Grade 100
GFR, Grade 2178190
GFR, Grade 32028
GFR, Grade 401
Hypercalcaemia, Grades 1 to 445
Hypercalcaemia, Grades 2 to 401
Hypercalcaemia, Grades 3 to 401
Hypercalcemia, Grade 144
Hypercalcaemia, Grade 200
Hypercalcaemia, Grade 300
Hypercalcaemia, Grade 401
Hyperglycaemia, Grades 1 to 410686
Hyperglycaemia, Grades 2 to 44938
Hyperglycaemia, Grades 3 to 433
Hyperglycaemia, Grade 15748
Hyperglycaemia, Grade 24635
Hyperglycaemia, Grade 322
Hyperglycaemia, Grade 411
Hyperkalemia, Grades 1 to 477
Hyperkalemia, Grades 2 to 421
Hyperkalemia, Grades 3 to 411
Hyperkalemia, Grade 156
Hyperkalemia, Grade 210
Hyperkalemia, Grade 301
Hyperkalemia, Grade 410
Hypernatremia, Grades 1 to 447
Hypernatremia, Grades 2 to 410
Hypernatremia, Grades 3 to 400
Hypernatremia, Grade 137
Hypernatremia, Grade 210
Hypernatremia, Grade 300
Hypernatremia, Grade 400
Hypocalcaemia, Grades 1 to 41721
Hypocalcaemia, Grades 2 to 4611
Hypocalcaemia, Grades 3 to 413
Hypocalcaemia, Grade 11110
Hypocalcaemia, Grade 258
Hypocalcaemia, Grade 312
Hypocalcaemia, Grade 401
Hypoglycaemia, Grades 1 to 42221
Hypoglycaemia, Grades 2 to 465
Hypoglycaemia, Grades 3 to 441
Hypoglycaemia, Grade 11616
Hypoglycaemia, Grade 224
Hypoglycaemia, Grade 330
Hypoglycaemia, Grade 411
Hypokalemia, Grades 1 to 495
Hypokalemia, Grades 2 to 401
Hypokalemia, Grades 3 to 400
Hypokalemia, Grade 194
Hypokalemia, Grade 201
Hypokalemia, Grade 300
Hypokalemia, Grade 400
Hyponatremia, Grades 1 to 42322
Hyponatremia, Grades 2 to 403
Hyponatremia, Grades 3 to 401
Hyponatremia, Grade 12319
Hyponatremia, Grade 202
Hyponatremia, Grade 300
Hyponatremia, Grade 401
LDL Cholesterol, Grades 1 to 46640
LDL Cholesterol, Grades 2 to 42113
LDL Cholesterol, Grades 3 to 462
LDL Cholesterol, Grade 14527
LDL Cholesterol, Grade 21511
LDL Cholesterol, Grade 362
LDL Cholesterol, Grade 400
Lactate Dehydrogenase, Grades 1 to 442
Lactate Dehydrogenase, Grades 2 to 430
Lactate Dehydrogenase, Grades 3 to 400
Lactate Dehydrogenase, Grade 112
Lactate Dehydrogenase, Grade 230
Lactate Dehydrogenase, Grade 300
Lactate Dehydrogenase, Grade 400
Lipase, Grades 1 to 47281
Lipase, Grades 2 to 43743
Lipase, Grades 3 to 4917
Lipase, Grade 13538
Lipase, Grade 22826
Lipase, Grade 3613
Lipase, Grade 434
Phosphate, Grades 1 to 47578
Phosphate, Grades 2 to 45051
Phosphate, Grades 3 to 477
Phosphate, Grade 12527
Phosphate, Grade 24344
Phosphate, Grade 377
Phosphate, Grade 400
Triglycerides, Grades 1 to 48975
Triglycerides, Grades 2 to 42215
Triglycerides, Grades 3 to 441
Triglycerides, Grade 16760
Triglycerides, Grade 21814
Triglycerides, Grade 341
Triglycerides, Grade 400
SecondaryNumber of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.

Time frame:
Up to Weeks 24, 48 and 96
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96
ParticipantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Week 2464
Week 4888
Week 961012
SecondaryNumber of Participants Who Discontinue Treatment Due to AEs Over Week 144

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Treatment Due to AEs Over Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of Participants Who Discontinue Treatment Due to AEs Over Week 1441316
SecondaryChange From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C and Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and at Weeks 24, 48
Reported as:
Least squares mean · Milligrams per Liter (mg/L)
Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48
Milligrams per Liter (mg/L)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Serum Cystatin C, Week 24, n=345,345-0.04 ± 0.0050.00 ± 0.005
Serum Cystatin C, Week 48, n=335,336-0.05 ± 0.005-0.04 ± 0.006
Serum RBP, Week 24, n=345,3431.2 ± 0.421.4 ± 0.48
Serum RBP, Week 48, n=334, 3340.6 ± 0.45-0.1 ± 0.42
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -0.03 · 95% CI -0.05 to -0.02Week 24. Serum Cystatin C.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.022 · Mean difference (net): -0.02 · 95% CI -0.03 to 0.00Week 48. Serum Cystatin C.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.797 · Mean difference (net): -0.2 · 95% CI -1.4 to 1.1Week 24. Serum RBP
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.258 · Mean difference (net): 0.7 · 95% CI -0.5 to 1.9Week 48. Serum RBP
SecondaryChange From Baseline in Renal Biomarker-Serum Cystatin C at Week 96

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.

Time frame:
Baseline and at Week 96
Reported as:
Mean · mg/L
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96
mg/LDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96-0.09 ± 0.006-0.08 ± 0.005
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.034 · Mean difference (net): -0.02 · 95% CI -0.03 to 0.00Week 96. Serum Cystatin C.
SecondaryChange From Baseline in Renal Biomarker-Serum Cystatin C at Week 144

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.

Time frame:
Baseline and at Week 144
Reported as:
Mean · mg/L
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144
mg/LDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144-0.11 ± 0.005-0.08 ± 0.006
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.006 · Mean difference (net): -0.02 · 95% CI -0.04 to -0.01Week 144. Serum Cystatin C.
SecondaryChange From Baseline in Renal Biomarker-Serum RBP at Week 96

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and at Week 96
Reported as:
Mean · Microgram per millimoles (ug/mmol)
Change From Baseline in Renal Biomarker-Serum RBP at Week 96
Microgram per millimoles (ug/mmol)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Change From Baseline in Renal Biomarker-Serum RBP at Week 960.557 ± 12.71392.483 ± 23.9105
SecondaryChange From Baseline in Renal Biomarker-Serum RBP at Week 144

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and at Week 144
Reported as:
Mean · Microgram per millimoles (ug/mmol)
Change From Baseline in Renal Biomarker-Serum RBP at Week 144
Microgram per millimoles (ug/mmol)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Renal Biomarker-Serum RBP at Week 1440.560 ± 9.59623.813 ± 10.8115
SecondaryChange From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48

Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI (GFR-cystatin C adjusted) and Serum or Plasma GFR from creatinine adjusted using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and at Weeks 24, 48
Reported as:
Mean · Milliliter/minute/1.73 meter^2
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48
Milliliter/minute/1.73 meter^2DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
GFR Cystatin C adjusted, Week 24, n=345,3453.8 ± 0.660.2 ± 0.65
GFR Cystatin C adjusted, Week 48, n=335,3365.4 ± 0.643.6 ± 0.64
GFR creatinine adjusted, Week 24, n=346,344-12.0 ± 0.64-15.4 ± 0.59
GFR creatinine adjusted, Week 48, n=335, 337-12.1 ± 0.60-15.4 ± 0.61
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): 3.6 · 95% CI 1.8 to 5.4Week 24. GFR Cystatin C adjusted.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.056 · Mean difference (net): 1.7 · 95% CI 0.0 to 3.5Week 48. GFR Cystatin C adjusted.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): 3.4 · 95% CI 1.7 to 5.2Week 24. GFR creatinine adjusted.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): 3.3 · 95% CI 1.6 to 5.0Week 48. GFR creatinine adjusted.
SecondaryChange From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96

Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and at Week 96
Reported as:
Mean · Milliliter/minute/1.73 meter^2
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96
Milliliter/minute/1.73 meter^2DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
GFR Cystatin C adjusted, Week 96, n=316,3269.1 ± 18.759.5 ± 13.95
GFR creatinine adjusted, Week 96, n=315,325-14.2 ± 12.69-17.5 ± 11.57
SecondaryChange From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144

Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and at Week 144
Reported as:
Mean · Milliliter/minute/1.73 meter^2
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144
Milliliter/minute/1.73 meter^2DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
GFR Cystatin C adjusted, Week 144, n=301,30410.3 ± 18.8210.1 ± 15.50
GFR creatinine adjusted, Week 144, n=292,292-15.5 ± 12.56-18.2 ± 11.73
SecondaryChange From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48

Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and at Weeks 24, 48
Reported as:
Mean · Micromoles per Liter (umol/L)
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48
Micromoles per Liter (umol/L)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Serum or Plasma Creatinine, Week 24, n=346, 34410.51 ± 0.54813.53 ± 0.507
Serum or Plasma Creatinine, Week 48, n=335, 33710.32 ± 0.51913.44 ± 0.540
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -3.02 · 95% CI -4.49 to -1.55Week 24. Serum or Plasma Creatinine
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -3.12 · 95% CI -4.59 to -1.65Week 48. Serum or Plasma creatinine
SecondaryChange From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96

Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented.

Time frame:
Baseline and at Week 96
Reported as:
Mean · Micromoles per Liter (umol/L)
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96
Micromoles per Liter (umol/L)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 9611.71 ± 0.56314.75 ± 0.526
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -3.04 · 95% CI -4.56 to -1.53Week 96. Serum or Plasma creatinine
SecondaryChange From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144

Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented.

Time frame:
Baseline and at Week 144
Reported as:
Mean · Micromoles per Liter (umol/L)
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144
Micromoles per Liter (umol/L)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 14412.28 ± 0.61315.14 ± 0.583
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = <0.001 · Mean difference (net): -2.86 · 95% CI -4.52 to -1.19Week 144. Serum or Plasma creatinine
SecondaryRatio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Geometric mean ratio and 95% CI of geometric mean ratio have been presented. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and Weeks 24, 48
Reported as:
Geometric mean · Ratio
Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48
RatioDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Serum B2M, Week 24, n=344,3460.809 (0.794 to 0.824)0.882 (0.867 to 0.898)
Serum B2M, Week 48, n=335,3360.811 (0.796 to 0.827)0.887 (0.871 to 0.904)
Urine B2M, Week 24, n=124,1060.844 (0.755 to 0.944)1.129 (0.974 to 1.309)
Urine B2M, Week 48, n=109, 1030.917 (0.804 to 1.046)1.323 (1.066 to 1.642)
Urine Albumin/Creatinine, Week 24, n=259, 2510.907 (0.844 to 0.976)1.021 (0.940 to 1.109)
Urine Albumin/Creatinine , Week 48, n=249, 2400.911 (0.835 to 0.994)0.971 (0.891 to 1.058)
Urine B2M/Urine Creatinine , Week 24, n=122, 1040.880 (0.779 to 0.993)1.126 (0.988 to 1.282)
Urine B2M/Urine Creatinine , Week 48, n=108, 1030.969 (0.854 to 1.099)1.307 (1.077 to 1.586)
Urine Phosphate, Week 24, n=343, 3401.041 (0.955 to 1.134)1.063 (0.978 to 1.157)
Urine Phosphate, Week 48, n=335, 3321.121 (1.031 to 1.220)1.056 (0.974 to 1.144)
Urine Protein/Creatinine, Week 24, n=263,2790.818 (0.779 to 0.859)0.991 (0.941 to 1.043)
Urine Protein/Creatinine , Week 48, n=259, 2610.866 (0.818 to 0.917)1.007 (0.954 to 1.062)
Urine RBP 4, Week 24, n=340, 3380.656 (0.591 to 0.729)0.824 (0.738 to 0.921)
Urine RBP 4, Week 48, n=333, 3310.740 (0.666 to 0.822)0.819 (0.730 to 0.919)
Urine RBP 4/Urine Creatinine, Week 24, n=338, 3350.670 (0.614 to 0.730)0.811 (0.741 to 0.888)
Urine RBP 4/Urine Creatinine, Week 48, n=331, 3280.749 (0.689 to 0.814)0.844 (0.774 to 0.920)
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.917 · 95% CI 0.893 to 0.941Week 24. Serum B2M.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.914 · 95% CI 0.890 to 0.939Week 48. Serum B2M.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.002 · Ratio of geometric means: 0.748 · 95% CI 0.621 to 0.901Week 24. Urine B2M.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.005 · Ratio of geometric means: 0.693 · 95% CI 0.538 to 0.892Week 48. Urine B2M.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.036 · Ratio of geometric means: 0.889 · 95% CI 0.796 to 0.992Week 24. Urine Albumin/Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.308 · Ratio of geometric means: 0.938 · 95% CI 0.830 to 1.061Week 48. Urine Albumin/Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.007 · Ratio of geometric means: 0.781 · 95% CI 0.654 to 0.934Week 24. Urine B2M/Urine Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.012 · Ratio of geometric means: 0.742 · 95% CI 0.588 to 0.935Week 48. Urine B2M/Urine Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.728 · Ratio of geometric means: 0.979 · 95% CI 0.868 to 1.104Week 24. Urine Phosphate.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.311 · Ratio of geometric means: 1.062 · 95% CI 0.945 to 1.194Week 48. Urine Phosphate.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.826 · 95% CI 0.769 to 0.887Week 24. Urine Protein/Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.860 · 95% CI 0.795 to 0.930Week 48. Urine Protein/Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.003 · Ratio of geometric means: 0.796 · 95% CI 0.683 to 0.927Week 24. Urine RBP 4
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.200 · Ratio of geometric means: 0.903 · 95% CI 0.773 to 1.056Week 48. Urine RBP 4
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.003 · Ratio of geometric means: 0.826 · 95% CI 0.728 to 0.936Week 24. Urine RBP 4/Urine Creatinine
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.052 · Ratio of geometric means: 0.888 · 95% CI 0.787 to 1.001Week 48. Urine RBP 4/Urine Creatinine
SecondaryRatio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and Week 96
Reported as:
Geometric mean · Ratio
Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96
RatioDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Urine Albumin/Creatinine, Week 96, n=239, 2430.939 (0.861 to 1.023)0.997 (0.914 to 1.087)
Urine B2M/Urine Creatinine, Week 96, n=101, 960.844 (0.757 to 0.941)1.259 (1.055 to 1.503)
Urine Phosphate, Week 96, n=316, 3221.156 (1.064 to 1.256)1.069 (0.988 to 1.156)
Urine Protein/Creatinine, Week 96, n=251, 2610.887 (0.836 to 0.942)1.016 (0.963 to 1.072)
Urine RBP 4/Urine Creatinine, Week 96, n=314, 3181.030 (0.953 to 1.113)1.287 (1.189 to 1.393)
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.338 · Ratio of geometric means: 0.942 · 95% CI 0.833 to 1.065Week 96. Urine Albumin/Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.671 · 95% CI 0.545 to 0.826Week 96. Urine B2M/Urine Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.174 · Ratio of geometric means: 1.082 · 95% CI 0.966 to 1.213Week 96. Urine Phosphate.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.873 · 95% CI 0.806 to 0.946Week 96. Urine Protein/Creatinine.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.800 · 95% CI 0.716 to 0.894Week 96. Urine RBP 4/Urine Creatinine
SecondaryRatio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline and at Week 144
Reported as:
Geometric mean · Ratio
Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144
RatioDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Urine Albumin/Creatinine, Week 144, n=230, 2211.036 (0.943 to 1.138)1.067 (0.973 to 1.169)
Urine B2M/Urine Creatinine, Week 144, n=108, 930.872 (0.792 to 0.960)1.494 (1.266 to 1.762)
Urine Phosphate, Week 144, n=301, 3011.083 (1.000 to 1.174)1.084 (0.999 to 1.175)
Urine Protein/Creatinine, Week 144, n=236, 2460.999 (0.947 to 1.054)1.180 (1.118 to 1.245)
Urine RBP 4/Urine Creatinine, Week 144, n=294, 2891.159 (1.083 to 1.240)1.567 (1.451 to 1.694)
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.658 · Ratio of geometric means: 0.971 · 95% CI 0.852 to 1.107Week 144. Urine Albumin/Creatinine.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.584 · 95% CI 0.483 to 0.706Week 144. Urine B2M/Urine Creatinine.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.993 · Ratio of geometric means: 1.000 · 95% CI 0.892 to 1.120Week 144. Urine Phosphate.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.847 · 95% CI 0.785 to 0.913Week 144. Urine Protein/Creatinine.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = <0.001 · Ratio of geometric means: 0.739 · 95% CI 0.667 to 0.819Week 144. Urine RBP 4/Urine Creatinine
SecondaryChange From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Micrograms per Liter (ug/L)
Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48
Micrograms per Liter (ug/L)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Bone-ALP, Week 24, n=345, 3460.72 ± 0.1713.38 ± 0.244
Bone-ALP, Week 48, n=334, 3371.24 ± 0.1984.33 ± 0.268
Serum Osteocalcin, Week 24, n=345, 3462.13 ± 0.3216.80 ± 0.368
Serum Osteocalcin, Week 48, n=335, 3360.40 ± 0.3266.30 ± 0.384
PINP, Week 24, n=344, 3461.7 ± 0.9515.2 ± 1.12
PINP, Week 48, n=335, 3370.4 ± 0.7913.3 ± 1.06
CTX-1, Week 24, n=342, 3420.1541 ± 0.012470.2812 ± 0.01406
CTX-1, Week 48, n=332, 3330.1345 ± 0.014960.3388 ± 0.01983
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -2.66 · 95% CI -3.25 to -2.08Week 24, Bone ALP
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -3.09 · 95% CI -3.75 to -2.44Week 48, Bone ALP
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -4.67 · 95% CI -5.63 to -3.71Week 28, Serum Osteocalcin
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -5.90 · 95% CI -6.89 to -4.91Week 48, Serum Osteocalcin
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -13.5 · 95% CI -16.4 to -10.6Week 24, Serum PINP
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -12.8 · 95% CI -15.4 to -10.2Week 48, Serum PINP
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -0.1270 · 95% CI -0.1640 to -0.0900Week 24, CTX-1
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -0.2043 · 95% CI -0.2532 to -0.1554Week 48, CTX-1
SecondaryChange From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Micrograms per Liter (ug/L)
Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96
Micrograms per Liter (ug/L)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Bone-ALP, Week 96, n=315, 3260.26 ± 0.1882.39 ± 0.234
Serum Osteocalcin, Week 96, n=315, 3260.13 ± 0.2863.90 ± 0.368
PINP, Week 96, n=315, 3257.0 ± 1.3719.5 ± 1.66
CTX-1, Week 96, n=311, 3180.0604 ± 0.010560.1787 ± 0.01403
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -2.13 · 95% CI -2.72 to -1.54Week 96, Bone ALP
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -3.77 · 95% CI -4.69 to -2.85Week 96, Serum Osteocalcin
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -12.6 · 95% CI -16.8 to -8.3Week 96, Serum PINP
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = <0.001 · Mean difference (net): -0.1183 · 95% CI -0.1529 to -0.0838Week 96, CTX-1
SecondaryChange From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Micrograms per Liter (ug/L)
Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144
Micrograms per Liter (ug/L)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Bone-ALP, Week 144, n=302, 305-0.25 ± 0.1561.88 ± 0.266
Serum Osteocalcin, Week 144, n=300, 304-1.02 ± 0.2802.87 ± 0.412
PINP, Week 144, n=299, 300-0.1 ± 0.949.4 ± 1.39
CTX-1, Week 144, n=291, 2980.0505 ± 0.011540.1868 ± 0.01516
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = <0.001 · Mean difference (net): -2.13 · 95% CI -2.74 to -1.53Week 144, Bone ALP
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = <0.001 · Mean difference (net): -3.89 · 95% CI -4.87 to -2.91Week 144, Serum Osteocalcin
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = <0.001 · Mean difference (net): -9.5 · 95% CI -12.8 to -6.2Week 144, Serum PINP
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = <0.001 · Mean difference (net): -0.1364 · 95% CI -0.1739 to -0.0988Week 144, CTX-1
SecondaryChange From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.

Time frame:
Baseline and at Weeks 24, 48
Reported as:
Least squares mean · Nanomoles per Liter (nmol/L)
Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48
Nanomoles per Liter (nmol/L)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Serum Vitamin D, Week 24, n=346, 34411.2 ± 1.0815.4 ± 1.33
Serum Vitamin D, Week 48, n=336, 3350.3 ± 0.920.4 ± 1.01
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.015 · Mean difference (net): -4.2 · 95% CI -7.5 to -0.8Week 24
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.960 · Mean difference (net): -0.1 · 95% CI -2.8 to 2.6Week 48
SecondaryChange From Baseline in Bone Biomarker-Serum Vitamin D at Week 96

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.

Time frame:
Baseline and at Week 96
Reported as:
Mean · Nanomoles per Liter (nmol/L)
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96
Nanomoles per Liter (nmol/L)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96-1.7 ± 1.011.3 ± 1.09
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.048 · Mean difference (net): -3.0 · 95% CI -5.9 to 0.0Week 96, Serum Vitamin D
SecondaryChange From Baseline in Bone Biomarker-Serum Vitamin D at Week 144

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.

Time frame:
Baseline and at Week 144
Reported as:
Mean · Nanomoles per Liter (nmol/L)
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144
Nanomoles per Liter (nmol/L)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 1441.1 ± 1.201.4 ± 1.22
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.887 · Mean difference (net): -0.2 · 95% CI -3.6 to 3.1Week 144, Serum Vitamin D
SecondaryPercentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma High Density Lipoprotein (HDL) Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value is defined as the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value).

Time frame:
Baseline and at Weeks 24, 48
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma High Density Lipoprotein (HDL) Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48
Percentage changeDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Serum or Plasma Cholesterol, Week 24, n=298, 3105.0 ± 16.85-4.5 ± 15.44
Serum or Plasma Cholesterol, Week 48, n=298, 3079.3 ± 17.10-3.3 ± 14.61
HDL Cholesterol, Direct, Week 24, n=299, 31013.9 ± 25.177.2 ± 32.22
HDL Cholesterol, Direct, Week 48, n=299, 30715.3 ± 23.754.0 ± 21.86
LDL Cholesterol, Week 24, n=298, 3093.8 ± 25.85-7.8 ± 21.13
LDL Cholesterol, Week 48, n=297, 30710.7 ± 27.54-4.1 ± 20.39
Triglycerides,Week 24, n=299, 3107.0 ± 40.450.5 ± 44.01
Triglycerides, Week 48, n=299, 3077.3 ± 46.92-0.3 ± 49.22
SecondaryChange From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Millimoles per liter
Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96
Millimoles per literDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Serum or Plasma Cholesterol, Week 96, n=270, 2890.345 ± 0.0356-0.132 ± 0.0375
HDL Cholesterol, Direct, Week 96, n=271, 2890.185 ± 0.01600.071 ± 0.0136
LDL Cholesterol, Week 96, n=270, 2890.139 ± 0.0308-0.160 ± 0.0304
Triglycerides, Week 96, n=271, 2890.105 ± 0.0488-0.102 ± 0.0365
SecondaryChange From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Millimoles per liter
Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144
Millimoles per literDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Serum or Plasma Cholesterol, Week 144, n=263, 2780.360 ± 0.0432-0.015 ± 0.0394
HDL Cholesterol, Direct, Week 144, n=264, 2780.180 ± 0.01620.093 ± 0.0136
LDL Cholesterol, Week 144, n=263, 2780.143 ± 0.0357-0.085 ± 0.0333
Triglycerides, Week 144, n=264, 2780.078 ± 0.0448-0.057 ± 0.0430
SecondaryPercentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value). Lipid last observation carried forwarded (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Participants on lipid-lowering agents at Baseline were excluded.

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48
Percentage changeDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Total/HDL Cholesterol Ratio, Week 24, n=298, 310-4.4 ± 22.53-7.5 ± 17.90
Total/HDL Cholesterol Ratio, Week 48, n=298, 307-2.8 ± 17.86-4.5 ± 18.25
SecondaryChange From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Ratio
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96
RatioDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96-0.113 ± 0.1552-0.395 ± 0.0473
SecondaryChange From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Ratio
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144
RatioDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144-0.245 ± 0.0545-0.359 ± 0.0533
SecondaryPercentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24 and 48 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 48 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48
Percentage of participantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Week 24, n=313, 32040
Week 48, n=324, 33242
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Fisher Exact · p = <0.001 · Mean difference (final values): 3.5 · 95% CI 1.5 to 5.6Week 24
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Fisher Exact · p = 0.037 · Mean difference (final values): 2.8 · 95% CI 0.2 to 5.4Week 48
SecondaryPercentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 96 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 96 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96
Percentage of participantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 9662
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Fisher Exact · p = 0.045 · Mean difference (final values): 3.1 · 95% CI 0.2 to 6.1Week 96
SecondaryPercentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 144 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 144 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144
Percentage of participantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 14464
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Fisher Exact · p = 0.160 · Mean difference (final values): 2.6 · 95% CI -0.8 to 6.0Week 144
SecondaryPercentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3 for group-1), Baseline HIV-1 RNA (\<=100000, \>100000 c/mL) and Race (White, African American/African heritage (H.), Asian other). Percentage values are rounded-off.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Baseline CD4+ cell count Group-1, <=200,n=32,267892
Baseline CD4+ cell count Group-1, >200,n=328,3339594
Female, n=54, 469389
Male, n=306, 3139495
Age, <35,n= 209, 2039394
Age, 35 to <50,n=115, 1229694
Age, >=50, n=36, 349491
Baseline plasma HIV-1 RNA, <=100000,n=294,2829495
Baseline plasma HIV-1 RNA, >100000,n=66, 779290
Race, White, n=240, 2529595
Race, African American/African H., n=51, 359089
Race, Asian, n=34, 309790
Race, Other, n=35, 428993
SecondaryPercentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3 for group-1), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48
Percentage of participantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Baseline CD4+ cell count Group-1, <=200,n=32, 267896
Baseline CD4+ cell count Group-1, >200,n=328,3339594
Female, n=54, 468987
Male, n=306, 3139495
Age, <35,n= 209,2039294
Age, 35 to <50,n=115, 1229794
Age, >=50, n=36, 348994
Baseline plasma HIV-1 RNA, <=100000,n=294,2829295
Baseline plasma HIV-1 RNA, >100000,n=66, 779790
Race, White, n=240, 2529696
Race, African American/African H., n=51, 358086
Race, Asian, n=34, 309790
Race, Other, n=35, 428690
SecondaryPercentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96
Percentage of participantsDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Baseline CD4+ cell count, <=200,n=32, 267285
Baseline CD4+ cell count, >200,n=328,3338990
Female, n=54, 468185
Male, n=306, 3138990
Age, <35,n= 209, 2038891
Age, 35 to <50,n=115, 1229089
Age, >=50, n=36, 348388
Baseline plasma HIV-1 RNA, <=100000,n=294, 2828891
Baseline plasma HIV-1 RNA, >100000,n=66, 778684
Race, White, n=240,2529291
Race, African American/African H., n=51, 356986
Race, Asian, n=34, 308890
Race, Other, n=35, 428983
SecondaryPercentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144
Percentage of participantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Baseline CD4+ cell count, <=200,n=32, 267569
Baseline CD4+ cell count, >200,n=328,3338586
Female, n=54, 467883
Male, n=306, 3138585
Age, <35,n= 209, 2038383
Age, 35 to <50,n=115, 1228685
Age, >=50, n=36, 348388
Baseline plasma HIV-1 RNA, <=100000,n=294, 2828485
Baseline plasma HIV-1 RNA, >100000,n=66, 778681
Race, White, n=240,2528887
Race, African American/African H., n=51, 356574
Race, Asian, n=34, 308583
Race, Other, n=35, 428979
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 24 by Subgroups

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Cells/mm^3
Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups
Cells/mm^3DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Baseline plasma HIV-1 RNA,<=100000, n=283,273186.01 ± 9.948148.21 ± 10.134
Baseline plasma HIV-1 RNA,>100000, n=66,72193.90 ± 20.811220.71 ± 19.814
Baseline CD4+ cell count,<=200, n=29, 26167.95 ± 31.308106.23 ± 32.990
Baseline CD4+ cell count,>200, n=320, 319189.91 ± 9.362167.35 ± 9.362
Age group, <35,n= 201, 193190.12 ± 11.829151.13 ± 12.050
Age group-1, 35 to <50, n=113, 119180.50 ± 15.733190.40 ± 15.404
Age group-1, >=50, n=35, 33198.74 ± 28.411133.21 ± 29.120
Female, n=52, 42213.58 ± 23.225153.92 ± 25.910
Male, n=297, 303183.41 ± 9.719164.18 ± 9.631
Race group, White, n=236, 243186.48 ± 10.932167.44 ± 10.790
Race group, African Am/African H., n=48, 34195.18 ± 24.222151.93 ± 28.784
Race group, Asian, n=33, 28154.03 ± 29.438141.24 ± 31.703
Race group, Other, n=32, 40222.21 ± 29.681160.20 ± 26.627
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 37.80 · 95% CI 9.98 to 65.62Baseline plasma HIV-1 RNA,\<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): -26.81 · 95% CI -82.72 to 29.10Baseline plasma HIV-1 RNA,\>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 61.72 · 95% CI -26.94 to 150.39Baseline CD4+ cell count,\<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 22.57 · 95% CI -3.42 to 48.55Baseline CD4+ cell count,\>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 38.99 · 95% CI 5.88 to 72.09Age Group,\<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): -9.90 · 95% CI -53.10 to 33.30Age Group,35 to \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 65.53 · 95% CI -14.43 to 145.50Age Group,\>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 59.66 · 95% CI -8.62 to 127.94Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 19.23 · 95% CI -7.65 to 46.10Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 19.04 · 95% CI -11.06 to 49.13Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 43.25 · 95% CI -30.59 to 117.09Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 12.80 · 95% CI -72.14 to 97.73Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 62.01 · 95% CI -16.09 to 140.12Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 48 by Subgroups

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from Analysis of Covariance (ANCOVA) model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Least squares mean · Cells/mm^3
Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups
Cells/mm^3DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Baseline plasma HIV-1 RNA,<=100000, n=273,271215.6 ± 10.67208.7 ± 10.71
Baseline plasma HIV-1 RNA,>100000, n=64,69261.8 ± 22.27248.7 ± 21.30
Baseline CD4+ cell count,<=200, n=28, 25210.9 ± 33.42153.2 ± 35.29
Baseline CD4+ cell count,>200, n=309, 315225.8 ± 10.00221.7 ± 9.89
Age group-1, <35,n= 193, 191234.2 ± 12.67201.7 ± 12.72
Age group-1, 35 to <50, n=112, 117212.7 ± 16.59244.2 ± 16.31
Age group-1, >=50, n=32, 32209.1 ± 31.20203.9 ± 31.06
Age group-2, <50,n= 305, 308226.4 ± 10.09217.8 ± 10.03
Age group-2, >=50, n= 32, 32208.5 ± 31.27204.1 ± 31.14
Female, n=48, 41236.2 ± 25.35263.6 ± 27.50
Male, n=289, 299222.8 ± 10.33210.0 ± 10.17
Race group, White, n=230, 244225.5 ± 11.62214.2 ± 11.30
Race group, African Am/African H., n=42, 31201.2 ± 27.16239.0 ± 31.64
Race group, Asian, n=33, 27204.9 ± 30.90189.3 ± 33.88
Race group, Other, n=32, 38270.2 ± 31.15232.6 ± 28.67
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 6.9 · 95% CI -22.7 to 36.6Baseline plasma HIV-1 RNA,\<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 13.2 · 95% CI -46.8 to 73.2Baseline plasma HIV-1 RNA,\>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 57.7 · 95% CI -37.2 to 152.5Baseline CD4+ cell count,\<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 4.1 · 95% CI -23.5 to 31.7Baseline CD4+ cell count,\>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 32.5 · 95% CI -2.7 to 67.7Age Group-1,\<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): -31.5 · 95% CI -77.1 to 14.2Age Group-1,35 to \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 5.2 · 95% CI -81.4 to 91.8Age Group-1,\>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 8.6 · 95% CI -19.4 to 36.5Age Group-2, \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 4.5 · 95% CI -82.3 to 91.3Age Group-2, \>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): -27.3 · 95% CI -100.8 to 46.1Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 12.8 · 95% CI -15.7 to 41.2Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 11.3 · 95% CI -20.4 to 43.1Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): -37.8 · 95% CI -119.6 to 44.0Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 15.6 · 95% CI -74.4 to 105.7Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 37.6 · 95% CI -45.4 to 120.5Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 96 by Subgroups

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · Cells/mm^3
Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups
Cells/mm^3DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Baseline plasma HIV-1 RNA,<=100000, n=259,260257.9 ± 12.47257.5 ± 12.45
Baseline plasma HIV-1 RNA,>100000, n=59,67312.1 ± 26.37297.4 ± 24.59
Baseline CD4+ cell count,<=200, n=25, 23229.4 ± 40.41202.9 ± 42.00
Baseline CD4+ cell count,>200, n=293, 304272.3 ± 11.73269.4 ± 11.50
Age group-1, <35,n= 186, 187266.0 ± 14.74257.7 ± 14.68
Age group-1, 35 to <50, n=101, 110273.6 ± 19.95286.8 ± 19.22
Age group-1, >=50, n=31, 30265.8 ± 36.14233.1 ± 36.61
Female, n=44, 40312.7 ± 30.12307.6 ± 31.67
Male, n=274, 287261.4 ± 12.07259.3 ± 11.81
Race group, White, n=221, 234272.1 ± 13.49258.3 ± 13.14
Race group, African Am/African H., n=35, 30246.3 ± 33.90303.7 ± 36.61
Race group, Asian, n=31, 27224.0 ± 36.31264.0 ± 38.57
Race group, Other, n=31, 36312.0 ± 36.01278.9 ± 33.56
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 0.5 · 95% CI -34.1 to 35.0Baseline plasma HIV-1 RNA,\<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 14.7 · 95% CI -55.6 to 84.9Baseline plasma HIV-1 RNA,\>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 26.5 · 95% CI -87.3 to 140.3Baseline CD4+ cell count,\<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 2.8 · 95% CI -29.4 to 35.1Baseline CD4+ cell count,\>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 8.3 · 95% CI -32.5 to 49.1Age Group,\<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): -13.3 · 95% CI -67.6 to 41.1Age Group,35 to \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 32.7 · 95% CI -68.5 to 133.9Age Group,\>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 5.1 · 95% CI -80.7 to 90.8Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 2.1 · 95% CI -31.1 to 35.3Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 13.7 · 95% CI -23.2 to 50.6Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): -57.4 · 95% CI -155.3 to 40.4Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): -40.1 · 95% CI -144.2 to 64.0Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · Mean difference (net): 33.1 · 95% CI -63.3 to 129.6Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 144 by Subgroups

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · Cells/mm^3
Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups
Cells/mm^3DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Baseline plasma HIV-1 RNA,<=100000, n=241,234286.8 ± 14.36277.8 ± 14.58
Baseline plasma HIV-1 RNA,>100000, n=55,58338.2 ± 30.34354.7 ± 29.35
Baseline CD4+ cell count,<=200, n=25, 19264.8 ± 44.91208.9 ± 51.25
Baseline CD4+ cell count,>200, n=271, 273300.3 ± 13.54297.9 ± 13.48
Age group, <35,n=171, 159302.9 ± 17.05277.1 ± 17.65
Age group-1, 35 to <50, n=95, 103292.8 ± 22.82329.2 ± 22.02
Age group-1, >=50, n=30, 30274.1 ± 40.71250.0 ± 40.60
Female, n=40, 37355.0 ± 34.93381.8 ± 36.37
Male, n=256, 255287.7 ± 13.81279.6 ± 13.85
Race group, White, n=202, 211300.0 ± 15.61296.5 ± 15.29
Race group, African Am/African H., n=34, 24256.4 ± 38.04377.6 ± 45.25
Race group, Asian, n=29, 25258.5 ± 41.57245.4 ± 44.36
Race group, Other, n=31, 32355.0 ± 39.84240.7 ± 39.35
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 9.1 · 95% CI -31.1 to 49.2Baseline plasma HIV-1 RNA,\<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -16.6 · 95% CI -98.9 to 65.8Baseline plasma HIV-1 RNA,\>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 56.0 · 95% CI -77.2 to 189.1Baseline CD4+ cell count,\<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 2.4 · 95% CI -35.2 to 39.9Baseline CD4+ cell count,\>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 25.8 · 95% CI -22.3 to 74.0Age Group,\<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -36.4 · 95% CI -98.6 to 25.8Age Group,35 to \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 24.1 · 95% CI -89.0 to 137.2Age Group,\>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -26.9 · 95% CI -125.9 to 72.2Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 8.1 · 95% CI -30.3 to 46.5Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 3.5 · 95% CI -39.4 to 46.3Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -121.2 · 95% CI -237.2 to -5.1Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 13.1 · 95% CI -106.4 to 132.6Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 114.3 · 95% CI 4.6 to 224.0Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
SecondaryChange From Baseline in European Quality of Life [EuroQoL] - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value.

Time frame:
Baseline (Day 1) and Weeks 4, 24, 48
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in European Quality of Life [EuroQoL] - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48
Scores on a scaleDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Week 4, n=359, 3550.0111 ± 0.003260.0130 ± 0.00510
Week 24, n=360, 3580.0207 ± 0.003100.0203 ± 0.00347
Week 48, n=360, 3580.0189 ± 0.003620.0208 ± 0.00342
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.759 · Mean difference (net): -0.0019 · 95% CI -0.0137 to 0.0100Week 4. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA , Baseline CD4+ cell count , and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.943 · Mean difference (net): 0.0003 · 95% CI -0.0088 to 0.0095Week 24. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA , Baseline CD4+ cell count , and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.703 · Mean difference (net): -0.0019 · 95% CI -0.0117 to 0.0079Week 48. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA , Baseline CD4+ cell count , and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
SecondaryChange From Baseline in EQ-5D-5L Utility Score at Week 96

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L Utility Score at Week 96
Scores on a scaleDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Change From Baseline in EQ-5D-5L Utility Score at Week 960.0168 ± 0.003390.0171 ± 0.00424
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.957 · Mean difference (net): -0.0003 · 95% CI -0.0110 to 0.0104Week 96. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
SecondaryChange From Baseline in EQ-5D-5L Utility Score at Week 144

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L Utility Score at Week 144
Scores on a scaleDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in EQ-5D-5L Utility Score at Week 1440.0210 ± 0.003460.0131 ± 0.00441
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.162 · Mean difference (net): 0.0079 · 95% CI -0.0032 to 0.0189Week 144. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
SecondaryChange From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24, 48

EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value.

Time frame:
Baseline (Day 1) and Weeks 4, 24, 48
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24, 48
Scores on a scaleDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Week 4, n=358, 3551.8 ± 0.503.1 ± 0.41
Week 24, n=359, 3583.9 ± 0.434.5 ± 0.48
Week 48, n=359, 3584.0 ± 0.434.6 ± 0.48
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.045 · Mean difference (net): -1.3 · 95% CI -2.6 to 0.0Week 4. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.358 · Mean difference (net): -0.6 · 95% CI -1.9 to 0.7Week 24. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.328 · Mean difference (net): -0.6 · 95% CI -1.9 to 0.6Week 48. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
SecondaryChange From Baseline in EQ-5D-5L Thermometer Scores at Week 96

EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96
Scores on a scaleDTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind Phase
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 964.4 ± 0.455.1 ± 0.52
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC - Double-blind Phase · MMRM · p = 0.318 · Mean difference (net): -0.7 · 95% CI -2.1 to 0.7Week 96. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
SecondaryChange From Baseline in EQ-5D-5L Thermometer Scores at Week 144

EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144
Scores on a scaleDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 1444.8 ± 0.444.5 ± 0.51
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.674 · Mean difference (net): 0.3 · 95% CI -1.0 to 1.6Week 144. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.

Adverse events

Collected over All-cause mortality, SAEs and non-SAEs were collected up to Week 148 in Double-blind Phase + Open-label Phase and from Week 148 to Week 280 in Continuation Phase. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG + 3TC - Double-blind Phase + Open-label Phase2/360 (0.6%)39/360 (10.8%)273/360 (75.8%)
DTG + TDF/FTC - Double-blind Phase + Open-label Phase1/359 (0.3%)47/359 (13.1%)276/359 (76.9%)
DTG + 3TC - Continuation Phase0/252 (0%)9/252 (3.6%)45/252 (17.9%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label PhaseDTG + 3TC - Continuation Phase
Suicide attemptPsychiatric disorders5/3602/3590/252
COVID-19Infections and infestations0/3600/3593/252
Suicidal ideationPsychiatric disorders1/3604/3590/252
Hepatitis AInfections and infestations3/3603/3591/252
Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3603/3590/252
Cholecystitis acuteHepatobiliary disorders0/3603/3590/252
PneumoniaInfections and infestations1/3602/3591/252
SeizureNervous system disorders0/3602/3590/252
CellulitisInfections and infestations0/3602/3590/252
Acute hepatitis CInfections and infestations2/3601/3590/252
Most frequent other events
Showing 10 of 74
Most frequent other events
EventDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label PhaseDTG + 3TC - Continuation Phase
NasopharyngitisInfections and infestations44/36069/3590/252
DiarrhoeaGastrointestinal disorders49/36053/3590/252
Upper respiratory tract infectionInfections and infestations47/36028/3597/252
HeadacheNervous system disorders33/36044/3590/252
PharyngitisInfections and infestations24/36033/3590/252
NauseaGastrointestinal disorders16/36031/3590/252
SyphilisInfections and infestations26/36030/35910/252
Vitamin D deficiencyMetabolism and nutrition disorders28/36020/3590/252
Back painMusculoskeletal and connective tissue disorders27/36023/3590/252
ArthralgiaMusculoskeletal and connective tissue disorders17/36025/3590/252

Baseline characteristics

Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind PhaseTotal
Mean34.6 ± 10.7234.4 ± 10.3534.5 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind PhaseTotal
Female5446100
Male306313619
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DTG + 3TC - Double-blind PhaseDTG + TDF/FTC - Double-blind PhaseTotal
American (Am) Indian or Alaska (Al.) native212950
Asian-Central/South Asian heritage (H.)033
Asian - East Asian H.282654
Asian - South East Asian H.617
Black or African Am513586
Native Hawaiian or other Pacific Islander011
White (Wt)-Arabic/North African H.336
Wt-Wt/Caucasian (Ca.)/European (Eu.) H.237249486
Multiple141226
09

Study locations

105 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294-3300, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Francisco, California 94109, United States
  • GSK Investigational Site
    San Leandro, California 94577, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    Washington, District of Columbia 20005, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Miami, Florida 33133, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Savannah, Georgia 31401, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Berkley, Michigan 48072, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63139, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Newark, New Jersey 07102, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267-0405, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77009, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Rosario, Santa Fe S2000PBJ, Argentina
  • GSK Investigational Site
    Buenos Aires, C1221ADC, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425 AWK, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Cordoba, 5000, Argentina
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Parramatta, New South Wales 2150, Australia
  • GSK Investigational Site
    Melbourne, Victoria Prahran 3181, Australia
  • GSK Investigational Site
    North Fitzroy, Victoria 3068, Australia
  • GSK Investigational Site
    Prahran, Victoria 3181, Australia
  • GSK Investigational Site
    Bruxelles, 1090, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Lodelinsart, 6042, Belgium
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Bobigny, 93009, France
  • GSK Investigational Site
    Lyon, 69317, France
  • GSK Investigational Site
    Paris Cedex 20, 75970, France
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53127, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50937, Germany
  • GSK Investigational Site
    Frankfurt/main, 60590, Germany
  • GSK Investigational Site
    Hamburg, 20099, Germany
  • GSK Investigational Site
    München, 81675, Germany
  • GSK Investigational Site
    Modena, Emilia-Romagna 41100, Italy
  • GSK Investigational Site
    Genova, Liguria 16128, Italy
  • GSK Investigational Site
    Milano, Lombardia 20142, Italy
  • GSK Investigational Site
    Milano, Lombardia 20157, Italy
  • GSK Investigational Site
    Torino, Piemonte 10149, Italy
  • GSK Investigational Site
    Bergamo, 24128, Italy
  • GSK Investigational Site
    Milano, 20162, Italy
  • GSK Investigational Site
    Monza, 20900, Italy
  • GSK Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • GSK Investigational Site
    Distrito Federal, 03720, Mexico
  • GSK Investigational Site
    Mexico, 14000, Mexico
  • GSK Investigational Site
    Lima, 1, Peru
  • GSK Investigational Site
    Lima, Callao 2, Peru
  • GSK Investigational Site
    Lima, Lima 13, Peru
  • GSK Investigational Site
    Bydgoszcz, 85-030, Poland
  • GSK Investigational Site
    Amadora, 2720-276, Portugal
  • GSK Investigational Site
    Lisboa, 1349-019, Portugal
  • GSK Investigational Site
    Porto, 4200-319, Portugal
  • GSK Investigational Site
    Bucharest, 021105, Romania
  • GSK Investigational Site
    Bucuresti, 30303, Romania
  • GSK Investigational Site
    Iasi, 700116, Romania
  • GSK Investigational Site
    Izhevsk, 426067, Russian Federation
  • GSK Investigational Site
    Kazan, 420061, Russian Federation
  • GSK Investigational Site
    Kemerovo, 650056, Russian Federation
  • GSK Investigational Site
    Krasnodar, 350015, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 193167, Russian Federation
  • GSK Investigational Site
    St.Peterburg, 190103, Russian Federation
  • GSK Investigational Site
    Alcorcon, 28922, Spain
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Granada, 18014, Spain
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Malaga, 29010, Spain
  • GSK Investigational Site
    Marid, 28040, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
  • GSK Investigational Site
    Valencia, 46010, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Bern, 3010, Switzerland
  • GSK Investigational Site
    Geneve, CH-1205, Switzerland
  • GSK Investigational Site
    Zuerich, 8091, Switzerland
  • GSK Investigational Site
    Kaohsiung, 807, Taiwan
  • GSK Investigational Site
    Kaohsiung, 813, Taiwan
  • GSK Investigational Site
    New Taipei, 220, Taiwan
  • GSK Investigational Site
    Tainan, 704, Taiwan
  • GSK Investigational Site
    Taipei, 11490, Taiwan
  • GSK Investigational Site
    Taoyuan, 330, Taiwan
  • GSK Investigational Site
    Woolwich, London, London SE18 4QH, United Kingdom
  • GSK Investigational Site
    Brighton, BN2 5BE, United Kingdom

Showing the first 100 of 105 sites across 18 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum In: Lancet. 2019 Jan 12;393(10167):132. doi: 10.1016/S0140-6736(18)33041-1. PubMed 30420123 ↗
  • Ait-Khaled M, Sierra Madero J, Estrada V, Gulminetti R, Hagins D, Tsai HC, Man C, Sievers J, Grove R, Zolopa A, Wynne B, van Wyk J. Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies. HIV Res Clin Pract. 2021 Dec 9;23(1):9-14. Epub 2021 Dec 16. PubMed 34913844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · viivhealthcare.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Apr 2018, 20 months.

Results were first posted in Apr 2019, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2016
First posted
Jul 13, 2016
StartActual
Jul 18, 2016
Primary completionActual
Apr 4, 2018
CompletionActual
Jun 29, 2022
Results first posted
Apr 22, 2019
Last update
Dec 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02831764
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 13, 2016
Start date
Jul 18, 2016
Primary completion
Apr 4, 2018
Completion
Jun 29, 2022
Results posted
Apr 22, 2019
Last update
Dec 7, 2023

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamivudine

Start the discussion